Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CIN-107 in primary aldosteronism
NCT04605549Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Mar 2021
- Primary completion
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of baxdrostat in primary aldosteronism (PA), sponsored by AstraZeneca. Primary endpoints: Treatment Emergent Adverse Events at 74 weeks and Change From Baseline in Mean Seated Systolic Blood Pressure at 12 weeks. Started Mar 2021; status: completed.
02
Drugs
baxdrostat
03
Conditions
primary aldosteronism (PA)
Beyond the preview
Go deeper on NCT04605549.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04605549.